

This listing of claims will replace all prior versions, and listings, of claims in the application:

Amendments to the Claims:

1-2. (Cancelled)

3. (Previously Presented) A compound of claim 18 wherein:

R^2 is (C₁-C₄)alkyl substituted with -NR⁴R⁵ or -C(=O)NR⁴R⁵;

R^4 is (C₁-C₆)alkyl substituted with -S(=O)CH₃, -NHC(=O)CH₃ or -C(=O)NR⁷R⁸;

R^5 is H or methyl; and

R^7 and R^8 are the same or different and are H or methyl.

4. (Cancelled)

5. (Previously Presented) A compound of claim 18 wherein:

R^2 is (C₁-C₆)alkyl substituted with -S(=O)R³;

R^3 is (C₁-C₆)alkyl optionally substituted with one to three groups selected from -S(=O)R⁶, -SO₂R⁶, -NR⁷R⁸, -OR⁷, -NR'C(=O)R⁷, -NR'SO₂R⁷; -C(=O)NR⁷R⁸; and -O-C(=O)NR⁷R⁸;

R^6 is (C₁-C₆)alkyl; and

R', R^7 and R^8 are the same or different and are H or (C₁-C₆)alkyl.

6. (Previously Presented) A compound of claim 18 wherein R^2 is (C₁-C₆)alkyl substituted with -S(=O)R³; and R^3 is (C₁-C₆)alkyl, preferably methyl.

7. (Cancelled)

8. (Previously Presented) A compound of claim 18 wherein:

R^2 is Q¹-Q²-Q³-Q⁴;

Q¹ is a single bond;

Q² is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q³ is -CH₂-;

Q⁴ is a 5-membered aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q² bound to Q¹ is a carbon atom; and

the atom of Q⁴ bound to Q³ is a carbon atom.

9. (Previously Presented) A compound of claim 18 wherein R¹ is -Cl or -F.
10. (Previously Presented) A compound of claim 18 wherein m is 2.
11. (Currently Amended) A compound according to claim 18 and selected from the group consisting of:

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
and

8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy})1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

and pharmaceutically acceptable salts thereof.


12. (Cancelled)

13. (Currently Amended) A method of treating ~~a disease is selected from T-cell-related diseases, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS) allergy, dermatoses, psoriasis, atopic dermatitis,~~ in a mammal, comprising administering to said mammal in need thereof a compound of claim 18.

14-16. (Cancelled)

17. (Previously Presented) A pharmaceutical composition comprising a compound of claim 18 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

18. (Currently Amended) A compound of formula (I):



wherein:

m is 1, 2 or 3;

R¹ is selected from CH₃, Cl, Br and F;

R² is selected from:

(a) Q¹-Q²-Q³-Q⁴ wherein:

Q¹ is a single bond or a linear or branched (C₁-C₆)alkylene group;

Q² is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom;

Q³ is a linear (C₁-C₄)alkylene group;

Q⁴ is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with a methyl;

the atom of Q^2 bound to Q^1 is a carbon atom; and

the atom of Q^4 bound to Q^3 is a carbon atom;

(b) (C_1-C_6) alkyl, said alkyl group being substituted with a group selected from OR^4 , $COOR^4$, NR^4R^5 , $NRC(=O)R^4$, $C(=O)NR^4R^5$ and $SO_2NR^4R^5$, wherein:

R is H or (C_1-C_6) alkyl;

R^4 is (C_1-C_6) alkyl substituted with 1 to 3 groups selected from $S(=O)R^6$, SO_2R^6 , $NR'C(=O)R^7$, $NR'SO_2R^6$, $C(=O)NR^7R^8$, $O-C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is (C_1-C_6) alkyl and R' , R^7 and R^8 are the same or different and are selected from H and (C_1-C_6) alkyl; and

R^5 is selected from R^4 , H and (C_1-C_6) alkyl;

(c) (C_1-C_6) alkyl, said alkyl group being:

substituted with 1 to 3 groups, preferably 1, selected from $OC(=O)R^{4a}$, SR^{4a} , $S(=O)R^3$, NR^aCOOR^{4a} , $NR^a-C(=O)-NR^{4a}R^{5a}$, $NR^a-SO_2-NR^{4a}R^{5a}$ and $NR^a-SO_2-R^3$, and

optionally substituted with OH or OCH_3 ;

wherein:

R^a is selected from H and CH_3 ;

R^3 is (C_1-C_6) alkyl, unsubstituted or substituted with 1 to 3 groups, selected from F, CN, $S(=O)R^6$, SO_3H , SO_2R^6 , $C(=O)-NH-SO_2-CH_3$, OR^7 , SR^7 , $COOR^7$, $C(=O)R^7$, $O-C(=O)NR^7R^8$, NR^7R^8 , $NR'C(=O)R^7$, $NR'SO_2R^6$, $C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is (C_1-C_6) alkyl and R' , R^7 and R^8 are the same or different and are selected from H and (C_1-C_6) alkyl;

R^{4a} and R^{5a} are the same or different and are selected from H and R^3 ;

their racemic forms, their isomers or their pharmaceutically acceptable salts, ~~solvates~~
and ~~hydrates~~.